Alzheimer's Disease Clinical Trials

Chronic insomnia and CSF markers of dementia - Phase 2

Longitudinal studies have found that sleep disturbance often precedes and increases risk for dementia by several years.The purpose of this study is to examine the relationship between chronic insomnia and dementia biomarkers and orexin levels found in cerebrospinal fluid (CSF).

Language And Cognitive Impairment In Parkinson's Disease

This study is designed to determine the changes in the brain that occur during conditions of verbal stimulation in patients who have Parkinson’s Disease and Parkinson’s Disease with Dementia or Dementia with Lewy Bodies.

A phase 2b double-blind randomised 5-arm vehicle-controlled dose ranging trial to evaluate the efficacy and safety of twice daily topical applications of delgocitinib cream 1 3 8 20 mg/g for 8 weeks in adult subjects with mild to severe atopic dermatitis.

The purpose of this clinical trial is to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects atopic dermatitis (a type of eczema). key eligibility include: Age 18 years and above. Diagnosis of AD …

A Phase 2 Multicenter Open-Label Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9orf72 Mutations Causative of Frontotemporal Dementia

Please see section 1 of protocol

A first in human phase 1 study in healthy volunteers and heterozygous carriers of a loss-of-function Granulin mutation causative of frontotemporal dementia to assess AL001 safety tolerability pharmacokinetics and pharmacodynamics

Please see section 1 of protocol

A Phase 3 Multicenter Randomized Double- Blind Placebo- Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene

This is for people who have a confirmed progranulin gene mutation that causes frontotemporal dementia (FTD). Study particiants will need to have a spouse, family member, or friend participate in this study with them as a study partner.

Four-Repeat Tauopathy Neuroimaging Initiative

New treatments that target the protein tau are beginning to enter human clinical trials. While tau-related therapies hold great promise for AD, clinical trials focusing on pure tauopathies are appealing because these diseases do not exhibit concurrent amyloid pathology. Pure 4 microtubule binding repeat (4R) tauopathies (4RT) include corticobasal degeneration …

Phase II Study to Assess the Safety Tolerability and Target Engagement of AMX0035 a Fixed Combination of Sodium Phenylbutyrate and Tauroursodeoxycholic Acid for the Treatment of Alzheimers Disease

This is a double blind, randomized, placebo controlled trial in subjects with mild cognitive impairment or dementia due to Alzheimer's disease (AD). AMX0035 is a combination of two compounds, Sodium Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA) that are hypothesized to prevent neuronal death through distinct pathways.

None

None